What happened with AVTR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Avantor supplies the materials and equipment customers need to conduct research, run tests and manufacture treatments. Laboratory Solutions generates most of its revenue, with Bioscience Production providing the other main business. Customers include biopharmaceutical and healthcare companies, universities, government institutions and technology manufacturers. Through VWR, they buy laboratory consumables and equipment sourced from Avantor and outside suppliers, and can pay for procurement, inventory management and onsite support.
Avantor also manufactures specialized materials, including J.T. Baker high-purity bioprocessing chemicals and NuSil silicone for human implants. It works with customers during development to tailor materials to their requirements; some become specified in customers’ approved production processes and continue to be purchased as those processes move into commercial production.
Most sales come from offerings Avantor considers recurring, but customers generally order without minimum purchase commitments and can stop buying. Revenue is spread across customers rather than dominated by one buyer. The business depends on continued laboratory and production activity, access to third-party supplies and materials that meet strict customer and regulatory standards. Avantor does not manufacture most of the products it sells, so supplier availability and terms matter. Exports of certain controlled goods also require prior approval under U.S. export-control rules.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Thermo Fisher Scientific competes for Avantor’s laboratory and biopharma customers through its Fisher Scientific distribution channel and life-science products, against VWR and Avantor’s own supplies. Watch its laboratory products and life-science sales for evidence of demand and competition in those customer groups.
Danaher competes with Avantor to supply laboratories and biological drug production, including products that move fluids through research and manufacturing processes. Its Biotechnology and Life Sciences results are the relevant areas to watch, rather than its Diagnostics business.
Repligen Corp competes with Avantor for biological drug manufacturers’ spending on fluid management, filtration and products that separate materials, known as chromatography. Sales in those product lines offer a closer comparison with Avantor’s Bioscience Production business than laboratory research equipment does.
Agilent Technologies competes with Avantor for research and analytical laboratories’ purchases of instruments, chromatography consumables and services that keep laboratory work running. Watch CrossLab consumables: most work with other manufacturers’ instruments, so their sales need not follow Agilent’s own instrument sales.
Bio-Rad Laboratories’ Life Science business competes with Avantor to sell reagents, consumables and equipment to biological research laboratories and biopharma manufacturers, including quality-control work. Focus on Life Science sales rather than the company total: that business accounted for approximately 40% of net sales in the year ended December 31, 2025.
Bio-Techne competes with Avantor for research, diagnostics and biological drug production customers buying life-science reagents and laboratory products. Its Protein Sciences business, which includes reagent and analytical products, is the larger area to watch, accounting for approximately 72% of net sales in fiscal 2026.
QIAGEN both competes with Avantor in products that prepare biological samples for testing and supplies reagents that Avantor sells to CareDx. Watch reagent supply disruptions: difficulties in Avantor’s supply from QIAGEN could force CareDx to reconfigure testing or interrupt sales.
Revvity competes with Avantor for pharmaceutical, biotechnology and academic customers buying research products and tools and services for laboratory work. Its Life Sciences sales to those customers are the relevant comparison, rather than its Diagnostics business.
Waters competes with Avantor for analytical laboratories’ purchases of chromatography columns, consumables and equipment used to separate and analyze samples. Watch column and consumable sales separately from instrument service and support, which represented over 35% of Waters sales in 2025.
Mettler-Toledo and Avantor both depend on life-science and chemical customers’ research and quality-control activity: the former sells precision laboratory instruments and services, while Avantor sells consumables and equipment. Watch its laboratory instruments and related services, which accounted for approximately 56% of net sales in 2025.
Bruker and Avantor depend on the budgets of life-science, biopharmaceutical and materials laboratories, which buy Bruker’s scientific instruments and Avantor’s laboratory supplies. Bruker’s sales to these laboratories can help gauge the spending backdrop for Avantor’s Laboratory Solutions business.
Charles River Laboratories and Avantor both need pharmaceutical and biotechnology research programs to advance and retain funding: customers pay Charles River for nonclinical discovery and safety testing, and Avantor for laboratory materials. Watch Charles River’s Discovery and Safety Assessment revenue for a view of activity in those programs.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher's laboratory-products and life-science sales will show whether the research and biopharma customers it shares with Avantor are still buying.
Focus on Thermo Fisher's laboratory-products and life-science sales, not Diagnostics. Stronger sales would suggest that shared research and biopharma customers are still buying, supporting demand in the market where Avantor's VWR channel competes, but would not prove Avantor won more orders. Weaker sales would point to a tighter purchasing environment for those customers and less demand support for Avantor's laboratory business.
Repligen Corp earningsRGEN
Repligen's fluid-management, filtration and chromatography sales will show how biological-drug manufacturers are spending in markets where it competes with Avantor's Bioscience Production business.
Focus on Repligen's sales in fluid management, filtration and chromatography. Stronger sales would indicate that biological-drug manufacturers are still buying these products, supporting demand in the market for Avantor's Bioscience Production offerings, though not proving Avantor's own sales rose. Weaker sales would point to softer customer spending or tougher competition for those purchases.
Avantor, Inc. earningsThis company
Avantor's report will show whether demand for its laboratory and bioprocessing products is recovering enough to lift sales and steady its gross margin.
Read organic sales in both segments alongside the overall gross margin. Rising sales with a steadier margin would show that customer orders are improving enough to absorb some cost and product-mix pressure. Falling sales and a further margin decline would show that weak demand and the cost of serving customers are still squeezing profitability.
Fed Interest Rate Decision
The Fed’s policy rate—the benchmark that guides borrowing costs—matters to Avantor because changes in rates can raise or lower interest paid on its variable-rate credit-facility debt, affecting cash left for operations and debt repayment.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is above expectations, higher rates can increase interest on Avantor’s variable-rate borrowings, leaving less cash for operations and principal repayment.
If it comes in below expectations
If the policy rate is below expectations, lower rates can reduce interest on Avantor’s variable-rate borrowings, leaving more cash for operations and principal repayment.
Bruker Corporation earningsBRKR
Bruker's instrument sales to life-science, biopharma and materials laboratories will show whether their research and quality-control spending is supporting demand for Avantor's laboratory supplies.
Look at Bruker's sales to life-science, biopharma and materials laboratories. Stronger sales would suggest that instrument buying, research and quality-control work at these labs are holding up, a supportive demand backdrop for the customers Avantor serves. Weaker sales would suggest those labs' budgets remain tight, limiting the chance that Avantor's supplies and equipment benefit from a recovery.
